Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Yubo International Biotech Limited (YBGJ : OTC)
 
 • Company Description   
MAGNA-LAB INC. is a development stage company. Co. has developed and now markets and intends to produce the MAGNA-SLn, the first of Co.'s proposed series of anatomy specific MRI (Magnetic Resonance Imaging) products which are smaller and cost less to own, install and operate than present ``whole body`` MRI systems.

Number of Employees: 20

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.09 Daily Weekly Monthly
20 Day Moving Average: 4 shares
Shares Outstanding: 118.18 (millions)
Market Capitalization: $10.27 (millions)
Beta: 4.40
52 Week High: $0.20
52 Week Low: $0.03
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.00% -3.79%
12 Week -2.25% -9.26%
Year To Date -8.53% -16.79%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Room 105 Building 5 31 Xishiku Avenue
-
Beijing,F4 100034
CHN
ph: 86-010-6615-5141
fax: 516-595-1159
None http://www.yubogroup.com
 
 • General Corporate Information   
Officers
Jun Wang - Chief Executive Officer; President and Director
Lina Liu - Chief Financial Officer; Treasurer and Director
Yang Wang - Director
Zhihui Bai - Director
Seymour Kessler - Director

Peer Information
Yubo International Biotech Limited (ABMD)
Yubo International Biotech Limited (DMDS)
Yubo International Biotech Limited (CPWY.)
Yubo International Biotech Limited (EQUR)
Yubo International Biotech Limited (ECIA)
Yubo International Biotech Limited (FMS)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 988366100
SIC: 3845
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/22
Next Expected EPS Date: 07/14/23
Share - Related Items
Shares Outstanding: 118.18
Most Recent Split Date: 3.00 (0.01:1)
Beta: 4.40
Market Capitalization: $10.27 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/14/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 41.72
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: 929.51%
vs. Previous Quarter: 135.45%
ROE
03/31/23 - -
12/31/22 - -
09/30/22 - -
ROA
03/31/23 - -30.83
12/31/22 - -33.04
09/30/22 - -40.54
Current Ratio
03/31/23 - 0.24
12/31/22 - 0.30
09/30/22 - 0.26
Quick Ratio
03/31/23 - 0.16
12/31/22 - 0.17
09/30/22 - 0.22
Operating Margin
03/31/23 - -383.08
12/31/22 - -1,155.51
09/30/22 - -460.24
Net Margin
03/31/23 - -383.08
12/31/22 - -1,155.51
09/30/22 - -460.24
Pre-Tax Margin
03/31/23 - -383.08
12/31/22 - -1,155.51
09/30/22 - -460.24
Book Value
03/31/23 - -0.01
12/31/22 - 0.00
09/30/22 - -0.01
Inventory Turnover
03/31/23 - 0.70
12/31/22 - 0.28
09/30/22 - 0.87
Debt-to-Equity
03/31/23 - -
12/31/22 - -
09/30/22 - -
Debt-to-Capital
03/31/23 - -
12/31/22 - -
09/30/22 - -
 

Powered by Zacks Investment Research ©